| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The target of Tetracosactide acetate is the melanocortin 2 receptor (MC2R) on the adrenal cortex. As a synthetic ACTH analog, it binds to MC2R and activates the cAMP signaling pathway, leading to the synthesis and release of corticosteroids, primarily cortisol. This mimics the biological activity of endogenous ACTH in stimulating the adrenal cortex.
|
|---|---|
| ln Vitro |
In vitro, Tetracosactide acetate is used to study the activation of the adrenal cortex and the release of corticosteroids. It is a standard reagent in assays measuring adrenocortical function. However, specific in vitro activity data are not detailed in the provided literature.
|
| ln Vivo |
In vivo, Tetracosactide acetate stimulates the adrenal glands to release corticosteroids, such as cortisol, in animals and humans. It is used as a diagnostic tool to assess adrenal function (ACTH stimulation test). It is being studied for therapeutic applications in ulcerative colitis, Crohn's disease, rheumatoid arthritis, and osteoarthropathy.
|
| Enzyme Assay |
The in vitro receptor binding assay for Tetracosactide acetate involves measuring its binding affinity to the melanocortin 2 receptor (MC2R). This is typically done using radiolabeled ligand competition assays on cells expressing MC2R. The compound’s ability to stimulate cAMP production in MC2R-expressing cells is also measured as a functional readout.
|
| Cell Assay |
In vitro cell-based assays for Tetracosactide acetate involve treating adrenal cortical cells with the compound and measuring corticosteroid production (e.g., cortisol) in the culture medium. This is used to assess the compound’s potency and efficacy in stimulating steroidogenesis.
|
| Animal Protocol |
In vivo animal studies for Tetracosactide acetate involve administering the compound to animals and measuring plasma corticosteroid levels. The compound is used in the ACTH stimulation test to assess adrenal function. In disease models, it is administered to evaluate its therapeutic effects on inflammation and autoimmune conditions.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Tetracosactide acetate are not detailed in the provided literature. As a peptide, it is typically administered by injection and has a short half-life. The acetate salt form is used to enhance stability and solubility.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for Tetracosactide acetate are available in the provided literature. As a peptide hormone analog, its safety profile is well-established for diagnostic use. The compound is for research use only.
|
| Additional Infomation |
Tetracosactide acetate is a synthetic ACTH analog used for research and diagnostic purposes. It stimulates corticosteroid release. It is being studied for various inflammatory conditions. It is for research use only. Its CAS number is 60189-34-6.
|
| Molecular Formula |
C138H214N40O33S
|
|---|---|
| Molecular Weight |
2993.48898839951
|
| Exact Mass |
1582.735
|
| CAS # |
60189-34-6
|
| Related CAS # |
Tetracosactide;16960-16-0
|
| PubChem CID |
87126289
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
43
|
| Hydrogen Bond Acceptor Count |
43
|
| Rotatable Bond Count |
96
|
| Heavy Atom Count |
212
|
| Complexity |
6540
|
| Defined Atom Stereocenter Count |
22
|
| SMILES |
S(C)CC[C@@H](C(N[C@@H](CCC(=O)O)C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CC1C=CC=CC=1)C(N[C@@H](CCCNC(=N)N)C(N[C@@H](CC1=CNC2C=CC=CC1=2)C(NCC(N[C@@H](CCCCN)C(N1CCC[C@H]1C(N[C@H](C(NCC(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCNC(=N)N)C(N[C@H](CCCNC(=N)N)C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC1C=CC(=CC=1)O)C(N1CCC[C@H]1C(=O)O)=O)=O)C(C)C)=O)CCCCN)=O)C(C)C)=O)=O)=O)=O)=O)=O)=O)C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CO)NC([C@H](CC1C=CC(=CC=1)O)NC(C(CO)N)=O)=O)=O.OC(C)=O
|
| InChi Key |
XDSGCNRPXJYVQS-GLMYKROOSA-N
|
| InChi Code |
InChI=1S/C136H210N40O31S.C2H4O2/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79;1-2(3)4/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151);1H3,(H,3,4)/t86-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,109-,110-,111-;/m0./s1
|
| Chemical Name |
acetic acid;(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3341 mL | 1.6703 mL | 3.3406 mL | |
| 5 mM | 0.0668 mL | 0.3341 mL | 0.6681 mL | |
| 10 mM | 0.0334 mL | 0.1670 mL | 0.3341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
